Twelve-month trial finds digital asthma programme significantly enhances symptom control in adults

Key Takeaways:

• A year-long decentralised trial found that a digital asthma self-management (DASM) programme significantly improved asthma control, particularly in individuals with uncontrolled asthma at baseline.
• Participants using the Apple Watch–integrated app saw greater improvements in Asthma Control Test (ACT) scores than those receiving usual care.
• The study highlights the importance of culturally responsive digital health solutions, as effectiveness varied across different ethnic groups.
  

A major decentralised clinical trial led by Elevance Health and the University of California, Irvine, in collaboration with Apple, Inc., has demonstrated that a digital asthma self-management (DASM) programme can meaningfully improve asthma symptom control in adults. The benefits were sustained over a 12-month period, making this one of the most substantial demonstrations to date of the potential for digital health technologies to enhance chronic disease management.

Trial Design and Participation

The randomised, controlled and virtual study enrolled 901 adult participants across 41 U.S. states. Participants included those with both commercial and Medicaid insurance, ensuring broad demographic representation. The intervention group used an iPhone application integrated with the Apple Watch, enabling them to:

• Track asthma-related health data
• Log symptoms
• Receive personalised alerts and reminders
  

This combination of continuous data monitoring and tailored prompts formed the core of the DASM approach, showcasing its scalability and potential for nationwide implementation.

Symptom Control Outcomes

The trial measured asthma control using the validated Asthma Control Test (ACT). Among individuals with uncontrolled asthma at baseline, those in the DASM group improved their ACT scores by an average of 4.6 points over 12 months, compared with only 1.8 points in the control group receiving standard care. Improvements of this magnitude typically indicate meaningful changes in symptoms—such as fewer episodes of breathlessness or reduced disruption to daily activities.

Even among those with controlled asthma at the outset, the DASM group showed favourable outcomes when compared with usual care, albeit with a smaller effect size.

Equity and Engagement Insights

Importantly, the study observed positive results across different insurance types and ethnicities, reinforcing the potential for DASM programmes to be deployed broadly. However, the improvements were less pronounced among African American participants, suggesting a need for culturally adaptive strategies in digital health design.

“These results support continued development of digital asthma self-management programmes,” said Dr Jordan Silberman, co-lead author and Director of Clinical Analytics at Elevance Health. “Findings also underscore the need for culturally adaptive strategies to ensure equitable engagement and impact across all communities affected by asthma.”

Secondary Benefits and Usage Patterns

Participants using the DASM intervention also experienced several secondary benefits, including:

• Improved medication adherence
• Greater confidence in managing their condition
• Reduced impact of asthma symptoms on work productivity
  

The researchers found that higher levels of app engagement—such as more frequent symptom logging—were strongly associated with better clinical outcomes.

“We are proud to support research that not only improves chronic disease management but prioritises underserved populations often left behind in digital innovation,” said Dr Richard A. Lee, co-author and Associate Clinical Professor of Pulmonary and Critical Care Medicine at UC Irvine.

Conclusion

This study presents compelling evidence for the role of digital technologies in long-term asthma management, especially when personalised, user-friendly tools are combined with wearable technology. It also highlights the critical importance of equity and inclusion in digital health to ensure that benefits are widely shared among all individuals living with asthma.